RxDoctor Payments Data

Mario Cote, MD

Internal Medicine · Spring Valley, ILNPI 1376514273

Payments from drug & device makers

$14,476in general payments, 2019–2025

Across 63 payments — averaging $229.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$14K
  • Novartis$62
  • AbbVie$58
  • Amarin Pharma, Inc.$45
  • AstraZeneca$44
  • Boehringer Ingelheim$39
  • plus $227 from 11 others

What the payments were for

  • Speaking & faculty fees$12,01883%
  • Travel & lodging$1,61411%
  • Food & beverage$8296%
  • Education$150%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,476 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$126,793
Medicare patients
606
Services billed
3,624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban437$421,814
JardianceEmpagliflozin267$295,584
OzempicSemaglutide136$191,274
RybelsusSemaglutide143$167,171
FarxigaDapagliflozin Propanediol112$124,666
MounjaroTirzepatide77$92,880
XareltoRivaroxaban69$82,765
Trelegy ElliptaFluticasone/Umeclidin/Vilanter85$67,116
Xultophy 100-3.6Insulin Degludec/Liraglutide31$59,079
Tresiba Flextouch U-200Insulin Degludec31$41,211
EntrestoSacubitril/Valsartan23$36,152
Tresiba Flextouch U-100Insulin Degludec44$30,253
TrulicityDulaglutide17$25,481
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr31$23,984
Soliqua 100-33Insulin Glargine/Lixisenatide20$21,936

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$421,814437 claims
Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6$14,001$417,525310 claims
Boehringer IngelheimJardiance, Spiriva Respimat$39$305,884283 claims
AstraZenecaFarxiga$44$124,666112 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta$12$107,419156 claims
Johnson & JohnsonXarelto$29$82,76569 claims
NovartisEntresto$62$36,15223 claims
AbbVieLinzess$58$15,37914 claims
MerckJanuvia$15$14,61911 claims
Astellas Pharma US IncMyrbetriq$14$13,57017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Spring Valley

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →